Expanded access for Zolgensma following final NICE guidance
NHS bodies in Wales and Northern Ireland are now expected to consider providing access to SMA gene therapy
Read More
Tag: Zolgensma
Zolgensma shows promise in presymptomatic SMA patients
Children treated with gene therapy prior to symptom presentation achieved motor milestones not seen in the natural history of SMA
Read More
NHS England agrees deal with Novartis for access to SMA gene therapy Zolgensma
NHS England has secured drug for use at a ‘substantial’ confidential discount
Read More
Novartis’ Zolgensma shows ‘continued benefit’ in SMA patients
66.7% of patients in the intent-to-treat population were able to feed orally without the need for feeding support
Read More
EU approves Novartis’ SMA gene therapy Zolgensma
Discussions with EU governments and reimbursement agencies are ongoing to agree on terms of an innovative ‘Day One’ access programme
Read More
Five-year Zolgensma data shows SMA benefit
If left untreated, SMA type I leads to death or the need for permanent ventilation by the age of two in more than 90% of cases.
Read More
Zolgensma wins FDA green light in child SMA
The $2.1 milllion per treatment price tag has garnered substantial criticism.
Read More
New data reinforce effectiveness of Novartis’ Zolgensma for SMA
The Phase III STR1VE data showed that 21 patients were alive and event-free as of September 27 last year.
Read More
Novartis’ SMA therapy gets US priority review
US regulators have accepted for review Novartis’ Biologics License Application for Zolgensma, an investigational gene replacement therapy for the treatment of spinal muscular atrophy (SMA) Type 1.
Read More
- Cure Parkinson’s convenes expert panel to assess £2 million combination therapy funding call
- Kygevvi approved in Europe as first treatment for TK2d
- Tozorakimab shows significant benefit in two major COPD trials
- Daratumumab becomes first oncology injectable approved for patient administration
- Laigo Bio completes final close of €17m seed financing round
